The European Food Safety Authority has given a green light to expanding the commercial applications of a genetically engineered food enzyme, potentially opening new markets for biotech companies while maintaining consumer safety standards. The decision affects food manufacturers, enzyme producers, and consumer advocacy groups who closely monitor genetically modified ingredients in the food chain.
Document details reveal scientific assessment process This scientific opinion was published on March 31, 2026, by EFSA's Panel on Food Contact Materials, Enzymes and Processing Aids (CEP). The document represents a non-binding scientific assessment that provides the technical basis for subsequent regulatory decisions by the European Commission and member states.
Scientific opinion prioritizes safety over market expansion The document contains concrete scientific findings rather than policy proposals, with specific numerical exposure limits (0.676 mg TOS/kg body weight per day) and detailed manufacturing process evaluations. The cleavage centers on expanding vs. restricting the use of genetically modified food enzymes, with EFSA prioritizing consumer safety assessment over commercial market access considerations.
Policy direction balances innovation with precaution The assessment demonstrates a regulatory approach that allows technological innovation in food processing while maintaining strict safety thresholds. This represents a middle ground between complete prohibition of genetically modified enzymes and unrestricted market access, favoring evidence-based expansion within defined safety parameters.
Stakeholders face mixed impacts from decision Novozymes A/S (the applicant) receives moderate positive impact through expanded commercial applications for their enzyme product. EU food manufacturers gain moderate positive impact with additional processing options, though with compliance costs. EU consumers experience minor positive impact through maintained safety standards, while national food safety authorities face moderate administrative burden in implementing the extended use authorization.
Institutional process continues with regulatory steps This scientific opinion represents a continuation of an ongoing regulatory process. The European Commission and member states will now consider EFSA's assessment for potential authorization decisions, with the Standing Committee on Plants, Animals, Food and Feed expected to deliberate on the technical basis provided.
← Atlas › News